Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1214 Neoplasms 1024 Carcinoma, Non-Small-Cell Lung 851 Prostatic Neoplasms 683 Colorectal Neoplasms 608 Lung Neoplasms 575 Neoplasm Metastasis 431 Multiple Myeloma 420 Leukemia, Myeloid, Acute 394 Pancreatic Neoplasms 371 Ovarian Neoplasms 359 Melanoma 317 Carcinoma, Hepatocellular 284 Recurrence 274 Squamous Cell Carcinoma of Head and Neck 272 Brain Neoplasms 264 Glioblastoma 245 Head and Neck Neoplasms 241 Stomach Neoplasms 236 Precursor Cell Lymphoblastic Leukemia-Lymphoma 226 Carcinoma, Renal Cell 225 Lymphoma 221 Triple Negative Breast Neoplasms 216 Endometrial Neoplasms 207 Hematologic Neoplasms 206 Urinary Bladder Neoplasms 195 Lymphoma, Non-Hodgkin 194 Sarcoma 189 Uterine Cervical Neoplasms 187 Glioma 187

Interventions

liposomal doxorubicin 1 defactinib 1 Paclitaxel 1 Letrozole 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Low Grade Serous Ovarian Cancer × 90 days × Clear all

NCT06072781 2026-04-02

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡